Metabolism of Ramelteon in Human Liver Microsomes and Correlation with the Effect of Fluvoxamine on Ramelteon Pharmacokinetics

@article{Obach2010MetabolismOR,
  title={Metabolism of Ramelteon in Human Liver Microsomes and Correlation with the Effect of Fluvoxamine on Ramelteon Pharmacokinetics},
  author={R. Obach and Tim F. Ryder},
  journal={Drug Metabolism and Disposition},
  year={2010},
  volume={38},
  pages={1381 - 1391}
}
  • R. Obach, Tim F. Ryder
  • Published 2010
  • Medicine, Chemistry
  • Drug Metabolism and Disposition
  • Ramelteon is a melatonin receptor agonist used as a treatment for insomnia. It is subject to a remarkably large drug-drug interaction (DDI) caused by fluvoxamine coadministration, resulting in a more than 100-fold increase in exposure. The objective of this study was to determine whether the DDI could be estimated using in vitro metabolism data. Ramelteon was shown to undergo hydroxylation in human liver microsomes to eight metabolites via six pathways. The main routes of metabolism included… CONTINUE READING
    Evaluation of a New Molecular Entity as a Victim of Metabolic Drug-Drug Interactions—an Industry Perspective
    • 43
    • PDF
    Pharmacological treatment of antipsychotic-induced dyslipidemia and hypertension
    • 21
    Artificial neural network cascade identifies multi-P450 inhibitors in natural compounds
    • 11
    • PDF

    References

    Publications referenced by this paper.
    SHOWING 1-10 OF 28 REFERENCES
    From the Food and Drug Administration.
    • 2,795
    • PDF
    Validated assays for human cytochrome P450 activities.
    • 436
    • PDF
    New Era in Drug Interaction Evaluation: US Food and Drug Administration Update on CYP Enzymes, Transporters, and the Guidance Process
    • 271
    • Highly Influential
    Kinetics of drug-drug interactions
    • 127
    Methods for predicting in vivo pharmacokinetics using data from in vitro assays.
    • 108
    • Highly Influential